Michael Wyzga

Mr. Michael S.
Wyzga is an Independent Director at Tvardi Therapeutics, Inc., an Independent Director at Carina Biotech Ltd., a Chairman at Mereo BioPharma Group Plc, a Lead Independent Director at X4 Pharmaceuticals, Inc., a President at Bioleap, Inc. (Florida), a Chairman at Gensight Biologics SA and a Chairman & Chief Financial Officer at Sporos Bioventures LLC.
He is on the Board of Directors at Tvardi Therapeutics, Inc., Carina Biotech Ltd., Glyscend, Inc., X4 Pharmaceuticals, Inc., Dohmen Co. and International Institute of New England, Inc. Mr. Wyzga was previously employed as an Independent Director by Invivyd, Inc., a Chairman by Arsanis, Inc., an Independent Director by LogicBio Therapeutics, Inc., a Chairman by X4 Pharmaceuticals, Inc. /Old/, an Independent Director by EXACT Sciences Corp., a Chief Financial Officer by Kew, Inc., a Member-Supervisory Board by Prosensa Holding NV, an Independent Director by Akebia Therapeutics, Inc., an Independent Director by OncoMed Pharmaceuticals, Inc., an Independent Director by Idenix Pharmaceuticals LLC, a President, Chief Executive Officer & Director by Radius Health, Inc., a Chief Financial Officer by Aura Biosciences, Inc., a Chief Financial Officer & Executive VP-Finance by Genzyme Corp., a Chief Financial Officer by Sovereign Hill Software, Inc., a Chief Financial Officer & Vice President by CacheLink Corp., a Vice President-Finance by Lotus Development Corp., and a Principal by Digital Equipment Corp.
He also served on the board at Tvardi Therapeutics, Inc. (Old), Altus Pharmaceuticals, Inc. and The Wang Center For The Performing Arts, Inc. He received his undergraduate degree from Suffolk University and an MBA from Providence College.